Sensus Healthcare, Inc. (SRTS): Price and Financial Metrics

Sensus Healthcare, Inc. (SRTS)

Today's Latest Price: $3.65 USD

0.19 (5.49%)

Updated Dec 3 12:56pm

Add SRTS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

SRTS Stock Summary

  • The price/operating cash flow metric for Sensus Healthcare Inc is higher than 97.06% of stocks in our set with a positive cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Sensus Healthcare Inc is reporting a growth rate of 157.77%; that's higher than 91.72% of US stocks.
  • As for revenue growth, note that SRTS's revenue has grown -51.59% over the past 12 months; that beats the revenue growth of just 4.77% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sensus Healthcare Inc are WTT, FEIM, XONE, QUMU, and SONM.
  • Visit SRTS's SEC page to see the company's official filings. To visit the company's web site, go to

SRTS Stock Price Chart Interactive Chart >

Price chart for SRTS

SRTS Price/Volume Stats

Current price $3.65 52-week high $4.99
Prev. close $3.46 52-week low $1.76
Day low $3.42 Volume 20,872
Day high $3.73 Avg. volume 27,216
50-day MA $2.72 Dividend yield N/A
200-day MA $2.78 Market Cap 60.23M

Sensus Healthcare, Inc. (SRTS) Company Bio

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is based in Boca Raton, Florida.

SRTS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.65$0 -100%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sensus Healthcare Inc. To summarize, we found that Sensus Healthcare Inc ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. The most interesting components of our discounted cash flow analysis for Sensus Healthcare Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is -399.33; that's higher than only 1.44% of US stocks in the Healthcare sector that have positive free cash flow.
  • Its compound free cash flow growth rate, as measured over the past 0.5 years, is -1% -- higher than only 0% of stocks in our DCF forecasting set.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 13.4% of US stocks with free cash flow have a lower reliance on debt in their capital structure.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

AGHC, ALC, AMRN, ATRS, and MOR can be thought of as valuation peers to SRTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

SRTS Latest News Stream

Event/Time News Detail
Loading, please wait...

SRTS Latest Social Stream

Loading social stream, please wait...

View Full SRTS Social Stream

Latest SRTS News From Around the Web

Below are the latest news stories about Sensus Healthcare Inc that investors may wish to consider to help them evaluate SRTS as an investment opportunity.

Sensus Healthcare EPS beats by $0.01, misses on revenue

Sensus Healthcare (SRTS): Q2 GAAP EPS of -$0.16 beats by $0.01.Revenue of $1.18M (-84.2% Y/Y) misses by $0.96M.Press Release...

Seeking Alpha | August 6, 2020

Sensus Healthcare Reports Second Quarter 2020 Financial Results

Conference call begins at 4:30 p.m. Eastern time today

GlobeNewswire | August 6, 2020

Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020

BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,…

GlobeNewswire | July 30, 2020

Evidence-Based Guidelines Issued by ASTRO Support Sensus Healthcare’s SRT Technology as the First-Line Alternative to Surgery for Treating Non-Melanoma Skin Cancer

Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomasBOCA RATON, Fla, July 14, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports that new guidelines issued by the American Society for Radiation Oncology (ASTRO) recommends SRT as the first-line alternative to surgery when treating patients with non-melanoma skin cancer (NMSC).  With more than 10,000 members, ASTRO is the world’s premier radiation oncology society and the authority on radiation therapy.“Over th...

Yahoo | July 14, 2020

Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th

BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19  webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.Sensus will participate in a panel discussion on Re-Engaging Medical Practices in an Era of COVID-19. As the country slowly begins to re-open, information is imperative. How and when will medical practices re-open, and to what extent? Will pent-up demand recoup some of the lost revenue? What are doctors observing as they re-engage with patie...

Yahoo | July 13, 2020

Read More 'SRTS' Stories Here

SRTS Price Returns

1-mo 52.72%
3-mo 46.00%
6-mo 21.67%
1-year -4.70%
3-year -28.99%
5-year N/A
YTD 3.11%
2019 -52.23%
2018 43.60%
2017 -1.71%
2016 N/A
2015 N/A

Continue Researching SRTS

Want to see what other sources are saying about Sensus Healthcare Inc's financials and stock price? Try the links below:

Sensus Healthcare Inc (SRTS) Stock Price | Nasdaq
Sensus Healthcare Inc (SRTS) Stock Quote, History and News - Yahoo Finance
Sensus Healthcare Inc (SRTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0495 seconds.